BioNTech’s Billion-Dollar Cash Pile Can’t Mask the Tension Ahead of Pumitamig Data
Published on 05/18/2026 at 05:03 | Redaktion boerse-global.de
The gap between Wall Street’s enthusiasm and the Frankfurt trading floor has rarely been wider for BioNTech. Fifteen of 19 analysts rate the stock a strong buy, with price targets stretching from $94 at TD Cowen to $158 at Canaccord Genuity. Yet the shares closed the week at €76.95, a whisker above their 52-week low and down roughly 11% over the past month. The 200-day moving average is now firmly in the rearview mirror.
That divergence reflects a defining crossroads for the Mainz-based company. The transition from pandemic-era vaccine champion to oncology specialist is consuming cash at a ferocious pace, but the balance sheet provides a rare luxury: at the end of March, BioNTech held €16.8 billion in liquid assets. That cushion gives management the freedom to fund a research budget that is expected to hit €2.5 billion in 2026 — a figure that will exceed projected annual revenue of €2.3 billion.
First?quarter numbers already show the strain. R&D costs surged past $650 million, while vaccine revenue dwindled to just $138 million, pushing the company deep into the red. The share price has lost nearly 7% since the start of the year, unable to shake the overhang of falling Covid?related sales.
Shareholders, however, have thrown their weight behind the strategic overhaul. At the recent annual general meeting, 92% of the capital present voted to expand the supervisory board from six to eight members. Iris Löw-Friedrich and Susanne Schaffert, both with deep oncology development and commercialisation experience, join the panel. The meeting also authorised a new capital increase of up to 50% of current share capital, giving the board flexibility to back a growing pipeline that now includes more than 20 late?stage clinical trials.
Should investors sell immediately? Or is it worth buying BioNTech?
Alongside that, a share?buyback programme of up to $1 billion has been authorised, running until May 2027. Berenberg analyst Harry Gillis calls the stock “deeply undervalued” and points to the pipeline’s potential, even after the bank trimmed its price target to $140.
What really matters, though, is the clinical data stream now moving into high gear. The first major catalyst arrives at the end of this month, when BioNTech presents Phase?2 results for its experimental bispecific antibody Pumitamig at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago. The embargo on advance abstracts lifts on 21 May, and the full presentation is set for 29 May.
The drug is being tested in the ROSETTA-Lung-02 trial, where it is paired with chemotherapy and pitted head?to?head against the established standard?of?care Keytruda (pembrolizumab) in first?line non?small cell lung cancer. A positive outcome would send a powerful signal that the company’s oncology bet is on the right track.
BioNTech at a turning point? This analysis reveals what investors need to know now.
The ASCO readout is just the first of seven late?stage data releases planned for this year. By December, BioNTech expects to have 15 Phase?3 studies running across its oncology pipeline. The founders Ugur Sahin and Ă–zlem TĂĽreci stepped back from day?to?day leadership at the end of the year to focus on a new mRNA project, but the company insists all patents and technology platforms remain firmly within the group.
With the stock trading near its floor and a wall of clinical catalysts ahead, the disconnect between analyst conviction and market pricing may soon resolve itself — one way or the other.
Ad
BioNTech Stock: New Analysis - 18 May
Fresh BioNTech information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
